Dr. Orelien is the CEO and President of ScitoVation, LLC a company that helps clients assess the safety of chemical products using in vitro and in silico methods (non-animal approaches). ScitoVation is the recognized leader in the use of innovative science and next-generation technology for assessing chemical safety. Clients of ScitoVation include the American Chemistry Council, the American Beverage Association and fortune 500 companies.
Prior to ScitoVation, Dr. Orelien served as CEO of SciMetrika, LLC a company he co-founded in 2001. SciMetrika was sold in September 2018 to Inoventures, a federal contractor based in northern Virginia. During Dr. Orelien’s tenure, SciMetrika achieved more than $100M in billings and performed on more than 150 federal contracts or task order awards. SciMetrika has received numerous awards for growth, including in 2010 the North Carolina Council for Entrepreneurial Development’s Companies to Watch, as well as Inc. magazine’s Top 500 Fastest Growing Companies in both 2010 and 2011. SciMetrika made the list of fastest growing companies in the Triangle four times finishing #2 in 2012.
Leslie Recio PhD DABT is the Chief Scientific Officer at Scitovation. Prior to Scitivoation, Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS. Dr. Recio obtained his B.S. in Microbiology and M.S. and Ph.D. in Toxicology from the University of Kentucky and has been Diplomat of the American Board of Toxicology (DABT) since 1998. Dr Recio is internationally recognized for his expertise in regulatory genetic toxicology, research in genetic and molecular toxicology and mode-of-action assessment using genomic technologies. He has served on the OECD Genetic Toxicology Expert Working Group since 2014. Dr. Recio was the PI for the National Toxicology Program (NTP) genetic toxicology testing more than for 17 yrs. In this role, Dr. Recio oversaw genotoxicity assessments of NTP test compounds in a battery of genetic toxicology assays following international regulatory testing guidelines. Dr. Recio has over 30 years of experience in toxicology research in the areas of mutagenesis, toxicogenomics, and regulatory genotoxicity assessments. His research program has included studies using primary and immortalized rodent and human cell lines, transgenic rodent models, and molecular genetic approaches to examine mechanisms and identify biomarkers of cytotoxicity, genotoxicity, and mutagenicity at the molecular, cellular, and animal level. His research program has focused on mode-of-action and the development of data useful for benchmark dose analysis to derive point of departure estimates used in risk assessments. More recently Dr. Recio has been committed to developing New Approach Methods to replace or reduce the reliance on animal testing by developing genotoxicity assessments in human hepatocyte models. In a collaboration with MIT (Bevin Engelward) and U of Ottawa (Carole Yauk), he has developed a human-relevant genotoxicity testing platform using metabolically competent human hepatocytes integrated with rapid detection of genotoxicity and mode-of-action based genomic profiling. Dr. Recio was appointed to the editorial boards of Mutagenesis, Toxicological Sciences and Mutation Research Reviews. He was appointed as an Associate Editor forToxicological Sciences from 2016-2019. He is a member of several scientific societies, including the Environmental Mutagen Society, the Society of Toxicology, and the Genetics and Environmental Mutagenesis Society, and has served several elected leadership positions, including GEMS President, President of the SOT Hispanic Organization of Toxicologists special interest group, and Council Member for the North Carolina Chapter of the Society of Toxicology.
Dr. Marjory Moreau is the Associate Director of the PMPK division at ScitoVation. Dr. Moreau’s research focuses on support and advances new human systems biology-based approaches to chemical safety assessment. This work combines research on in vitro biokinetic modeling, physiologically based pharmacokinetic modeling and quantitative in vitro to in vivo extrapolation modeling to translate non-animal and human cell-based toxicity testing results to safe human exposure estimates to support human health assessment.
She completed her Ph.D. in Public Health with a specialty in Toxicology at the University of Montreal, working on the quantitative relationship between exposure to BaP, the temporal evolution of biomarkers of exposure and the appearance of early biological alterations.
She finished her postdoctoral fellowship under the supervision of Andy Nong at Health Canada Computational Toxicology Laboratory. Marjory received support for her research work by the Natural Sciences and Engineering Research Council of Canada (NSERC) which focused on the application of pharmacokinetic models and high throughput screening results to evaluate the potential hazards of chemicals. This work also combined the in-vitro to in-vivo extrapolation approach with biomonitoring studies to bring forth into a public health context.
Jamie Scaglione, Ph.D., is the Associate Director of Cell-Based Assays. She and the cell-based team work with clients to customize toxicity assays to help assess chemical compound safety. She has a diverse scientific background that spans the interface of biology and chemistry and has co-authored numerous publications. Dr. Scaglione earned a Ph.D. in Chemical Biology from Washington University in St. Louis synthesizing and evaluating the activity of neurosteroid analogues. She conducted postdoctoral research at the University of Michigan analyzing microbial natural product biosynthetic pathways. When not in the lab, she enjoys gardening and spending time with her family.
Dr. Jeffrey Fisher is currently a Senior Science Fellow at ScitoVation. Prior to joining, Dr. Fisher was a biomedical research service employee (Research Toxicologist) with the U.S. Food and Drug Administration, National Center for Toxicological Research. He was formerly a Professor in the Department of Environmental Health Science, College of Public Health at the University of Georgia (UGA). He joined the University of Georgia in 2000 and served as Department Head of the Department of Environmental Health Sciences from 2000 to 2006 and Director of the Interdisciplinary Toxicology Program at UGA from 2006-2010. From 1975 to 2000 he worked at a toxicology laboratory, Wright Patterson AFB. He started working as a technician, then progressed to principal investigator and senior scientist in the Toxics Hazards Division before becoming the Technical Advisor for the Operational Toxicology Branch.
Melvin (Mel) Andersen, Ph.D. is Senior Program Advisor at ScitoVation. He has almost 50 years experience in toxicology and risk assessment, primarily developing and applying physiologically based pharmacokinetic and biologically based pharmacodynamic (PBPK) models in quantitative safety assessments. He has worked in the federal government, private industry and academia. In 2007, Dr. Andersen co-authored a National Research Council report, “Toxicity Testing in the 21st Century: A Vision and a Strategy,” and now works with clients to apply new alternative methods (NAMs) and toxicity pathway-based approaches outlined in this report to support chemical safety assessments.
Mel works with clients to assess MOAs using time and dose-related changes in gene expression in cells and tissues, suggests approaches to use NAMs in human health risk assessment and continues his career-long interest in using PK models in safety assessment. Dr. Andersen has received many awards for professional contributions, including the Frank Blood (1982), Achievement (1984), Arnold J. Lehman (2004) and Merit Awards (2016) from the Society of Toxicology and the Mildred Christian Award for career achievements from the Academy of Toxicological Sciences.
He is a certified industrial hygienist, a diplomate of the American Board of Toxicology and Fellow of the Academy of Toxicological Sciences. He has a Ph.D. in biochemistry and molecular biology from Cornell University.